{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:19:53Z","timestamp":1791199193470,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,2,27]],"date-time":"2008-02-27T00:00:00Z","timestamp":1204070400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Guidelines established for the treatment of HIV-1 infection and genotype interpretation do not apply for HIV-2. Data about antiretroviral (ARV) drug efficacy and resistance mutations is scarce.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical data about HIV-2 infected patients in Belgium and Luxembourg were collected and the effect of ARV therapy on plasma viral load and CD4 counts were analysed. Viral RNA encoding for protease (PR) and reverse transcriptase (RT) from ARV-na\u00efve and treated patients were sequenced.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty-five HIV-2 infected patients were included in this cohort. Twenty patients were treated with 25 different ARV combinations in a total of 34 regimens and six months after the start of ARV therapy, only one third achieved viral load suppression. All of these successful regimens bar one contained protease inhibitors (PIs). Mean CD4 gains in the group of viral load suppressors and the group of patients treated with PI-containing regimens were respectively significantly higher than in the group of non-suppressors and the group of PI-sparing regimens. The most frequent mutations selected under therapy (compared to HIV-2 ROD) were V71I, L90M and I89V within PR. Within RT, they were M184V, Q151M, V111I and K65R. All of these mutations, except K65R and M184V, were also found in variable proportions in ARV-na\u00efve patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite a high rate of ARV treatment failure, better virological and immunological results were achieved with PI-containing regimens. The analysis of polymorphic positions and HIV-2 specific mutations selected during therapy showed for the first time that transmission of drug resistant viruses has occurred in Belgium and Luxembourg. The high heterogeneity in ARV combinations reflects a lack of guidelines for the treatment of HIV-2 infection.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2334-8-21","type":"journal-article","created":{"date-parts":[[2008,2,27]],"date-time":"2008-02-27T19:13:50Z","timestamp":1204139630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database"],"prefix":"10.1186","volume":"8","author":[{"given":"Jean","family":"Ruelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Th\u00e9r\u00e8se","family":"Vandenbroucke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Fransen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedoua","family":"Echahidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Pi\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Verhofstede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristel","family":"Van Laethem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Luce","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolor\u00e8s","family":"Vaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Schmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Goubau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,2,27]]},"reference":[{"key":"612_CR1","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1056\/NEJM198705073161903","volume":"316","author":"F Clavel","year":"1987","unstructured":"Clavel F, Mansinho K, Chamaret S, Guetard D, Favier V, Nina J, Santos-Ferreira MO, Champalimaud JL, Montagnier L: Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med. 1987, 316: 1180-1185.","journal-title":"N Engl J Med"},{"key":"612_CR2","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1126\/science.7915856","volume":"265","author":"R Marlink","year":"1994","unstructured":"Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia MC, Gueye EH, Hellinger J, Gu\u00e8ye-Ndiaye A, Sankal\u00e9 JL, Ndoye I, Mboup S, Essex M: Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science. 1994, 265: 1587-1590. 10.1126\/science.7915856.","journal-title":"Science"},{"key":"612_CR3","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1001\/jama.1993.03510170073033","volume":"270","author":"KM De Cock","year":"1993","unstructured":"De Cock KM, Adjorlolo G, Ekpini E, Sibailly T, Kouadio J, Maran M, Brattegaard K, Vetter KM, Doorly R, Gayle HD: Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. JAMA. 1993, 270: 2083-2086. 10.1001\/jama.270.17.2083.","journal-title":"JAMA"},{"key":"612_CR4","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1097\/00002030-199311000-00002","volume":"7","author":"F Simon","year":"1993","unstructured":"Simon F, Matheron S, Tamalet C, Loussert-Ajaka I, Bartczak S, P\u00e9pin JM, Dhiver C, Gamba E, Elbim C, Gastaut JA, Saimot A, Brun-V\u00e9zinet F: Cellular and plasma viral load in patients infected with HIV-2. AIDS. 1993, 7: 1411-1417. 10.1097\/00002030-199311000-00002.","journal-title":"AIDS"},{"key":"612_CR5","unstructured":"Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. DHHS. Revised May 4, 2006., [http:\/\/aidsinfo.nih.gov\/guidelines]"},{"key":"612_CR6","doi-asserted-by":"publisher","first-page":"14410","DOI":"10.1073\/pnas.222366699","volume":"99","author":"J Ren","year":"2002","unstructured":"Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK: Structure of HIV-2 reverse transcriptase at 2.35-\u00c5 resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci USA. 2002, 99: 14410-14415. 10.1073\/pnas.222366699.","journal-title":"Proc Natl Acad Sci USA"},{"key":"612_CR7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350400900115","volume":"9","author":"M Witvrouw","year":"2004","unstructured":"Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W: Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004, 9: 57-65.","journal-title":"Antivir Ther"},{"key":"612_CR8","volume-title":"XV International HIV drug resistance workshop : basic principles and clinical implications: 13\u201317","author":"D Descamps","year":"2006","unstructured":"Descamps D: In vitro phenotypic susceptibility of HIV-2 clinical isolates to protease inhibitors: amprenavir, atazanavir, lopinavir and tipranavir [abstract 93]. XV International HIV drug resistance workshop : basic principles and clinical implications: 13\u201317. 2006, June ; Sitges, Spain"},{"key":"612_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1128\/AAC.00870-06","volume":"51","author":"M Ntemgwa","year":"2007","unstructured":"Ntemgwa M, Brenner BG, Oliveira M, Moisi D, Wainberg MA: Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother. 2007, 51: 604-610. 10.1128\/AAC.00870-06.","journal-title":"Antimicrob Agents Chemother"},{"key":"612_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/jac\/dkl034","volume":"57","author":"B Rod\u00e9s","year":"2006","unstructured":"Rod\u00e9s B, Sheldon J, Toro C, Jim\u00e9nez V, Alvarez A, Soriano V: Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother. 2006, 57: 709-713. 10.1093\/jac\/dkl034.","journal-title":"J Antimicrob Chemother"},{"key":"612_CR11","doi-asserted-by":"crossref","unstructured":"Adj\u00e9-Tour\u00e9 CA, Cheingsong R, Garcia-Lerma JG, Eholi\u00e9 S, Borget MY, Bouchez JM, Otten RA, Maurice C, Sassan-Morokro M, Ekpini RE, Nolan M, Chorba T, Heneine W, Nkengasong JN: Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS. 2003, S49-54. Suppl 3","DOI":"10.1097\/00002030-200317003-00007"},{"key":"612_CR12","volume-title":"14th conference on Retroviruses and opportunistic infections, 25\u201328","author":"D Desbois","year":"2007","unstructured":"Desbois D, Peytavin G, Matheron S, Damond F, Collin G, B\u00e9nard A, Campa P, Ch\u00eane G, Brun-V\u00e9zinet F, Diane Descamps , The French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2): Phenotypic Susceptibility in vitro to Amprenavir, Atazanavir, Darunavir, Lopinavir, and Tipranavir of HIV-2 Clinical Isolates from the French ANRS HIV-2 Cohort [abstract 615]. 14th conference on Retroviruses and opportunistic infections, 25\u201328. 2007, February ; Los Angeles, USA"},{"issue":"Suppl 1","key":"612_CR13","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1002\/jmv.20599","volume":"78","author":"FE McCutchan","year":"2006","unstructured":"McCutchan FE: Global epidemiology of HIV. J Med Virol. 2006, 78 (Suppl 1): S7-S12. 10.1002\/jmv.20599.","journal-title":"J Med Virol"},{"key":"612_CR14","volume-title":"14th conference on Retroviruses and opportunistic infections, 25\u201328","author":"F Damond","year":"2007","unstructured":"Damond F, B\u00e9nard A, on behalf of the ACHIeV2e study group: Quality control assessment of HIV-2 viral load quantification assays : Results from an international collaboration on HIV-2 infection, 2006 [Abstract 676]. 14th conference on Retroviruses and opportunistic infections, 25\u201328. 2007, February ; Los Angeles, USA"},{"key":"612_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1128\/JCM.01613-06","volume":"45","author":"B Rod\u00e9s","year":"2007","unstructured":"Rod\u00e9s B, Sheldon J, Toro C, Cuevas L, P\u00e9rez-Pastrana E, Herrera I, Soriano V: Quantitative detection of plasma human immunodeficiency virus type 2 subtype A RNA by the Nuclisens EasyQ Assay (version 1.1). J Clin Microbiol. 2007, 45: 88-92. 10.1128\/JCM.01613-06.","journal-title":"J Clin Microbiol"},{"key":"612_CR16","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1097\/01.aids.0000233582.64467.8e","volume":"20","author":"S Jallow","year":"2006","unstructured":"Jallow S, Kaye S, Alabi A, Aveika A, Sarge-Njie R, Sabally S, Corrah T, Whittle H, Vanham G, Rowland-Jones S, Janssens W, McConkey SJ: Virological and immunolgical response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS. 2006, 20: 1455-1458. 10.1097\/01.aids.0000233582.64467.8e.","journal-title":"AIDS"},{"key":"612_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/01.aids.0000199829.57112.2f","volume":"20","author":"S Matheron","year":"2006","unstructured":"Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, Pueyo S, Brun-Vezinet F, Chene G, ANRS CO5 HIV2 Cohort Study Group: CD4 cell recovery in treated HIV-2 infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS. 2006, 20: 459-462. 10.1097\/01.aids.0000199829.57112.2f.","journal-title":"AIDS"},{"key":"612_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.medmal.2005.11.012","volume":"36","author":"CT Ndour","year":"2006","unstructured":"Ndour CT, Batista G, Manga NM, Gu\u00e8ye NF, Badiane NM, Fortez L, Sow PS: Efficacy and tolerance of antiretroviral therapy in HIV-2 infected patients in Dakar: preliminary study. Med Mal Infect. 2006, 36: 111-114.","journal-title":"Med Mal Infect"},{"key":"612_CR19","doi-asserted-by":"crossref","unstructured":"van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, Niesters HG, Osterhaus AD, Schutten M: Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS. 2003, S55-S61. Suppl 3","DOI":"10.1097\/00002030-200317003-00008"},{"key":"612_CR20","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1097\/00002030-200205240-00016","volume":"16","author":"SC Houston","year":"2002","unstructured":"Houston SC, Miedzinski LJ, Mashinter LD: Rapid progression of CD4 cell decline and subsequent response to salvage therapy in HIV-2 infection. AIDS. 2002, 16: 1189-1191. 10.1097\/00002030-200205240-00016.","journal-title":"AIDS"},{"key":"612_CR21","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1086\/421390","volume":"38","author":"C Mullins","year":"2004","unstructured":"Mullins C, Eisen G, Popper S, Dieng Sarr A, Sankale JL, Berger JJ, Wright SB, Chang HR, Coste G, Cooley TP, Rice P, Skolnik PR, Sullivan M, Kanki PJ: Highly active antiretroviral therapy and viral response in HIV type 2 infection. Clin Infect Dis. 2004, 38: 1771-1779. 10.1086\/421390.","journal-title":"Clin Infect Dis"},{"key":"612_CR22","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1086\/511308","volume":"195","author":"A Macneil","year":"2007","unstructured":"Macneil A, Sankale JL, Meloni ST, Sarr AD, Mboup S, Kanki P: Long-Term Intrapatient Viral Evolution during HIV-2 Infection. J Infect Dis. 2007, 195: 726-733. 10.1086\/511308.","journal-title":"J Infect Dis"},{"key":"612_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/00002030-200402200-00016","volume":"18","author":"D Pieniazek","year":"2004","unstructured":"Pieniazek D, Rayfield M, Hu DJ, Nkengasong JN, Soriano V, Heneine W, Zeh C, Agwale SM, Wambebe C, Odama L, Wiktor SZ: HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS. 2004, 18: 495-502. 10.1097\/00002030-200402200-00016.","journal-title":"AIDS"},{"key":"612_CR24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jmv.20296","volume":"75","author":"P Colson","year":"2005","unstructured":"Colson P, Henry M, Tivoli N, Gallais H, Gastaut JA, Moreau J, Tamalet C: Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France. J Med Virol. 2005, 75: 381-390. 10.1002\/jmv.20296.","journal-title":"J Med Virol"},{"key":"612_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1742-4690-3-58","volume":"3","author":"N BenM'Barek","year":"2006","unstructured":"BenM'Barek N, Audoly G, Raoult D, Gluschankof P: HIV-2 Protease resistance defined in yeast cells. Retrovirology. 2006, 3: 58-10.1186\/1742-4690-3-58.","journal-title":"Retrovirology"},{"key":"612_CR26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1128\/JCM.43.1.484-487.2005","volume":"43","author":"F Damond","year":"2005","unstructured":"Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S, Mammano F, Lastere S, Farfara I, Simon F, Chene G, Descamps D: Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2 infected patients treated with protease inhibitors. J Clin Microb. 2005, 43: 484-487. 10.1128\/JCM.43.1.484-487.2005.","journal-title":"J Clin Microb"},{"key":"612_CR27","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1128\/JCM.42.2.570-577.2004","volume":"42","author":"P Colson","year":"2004","unstructured":"Colson P, Henry M, Tourres C, Lozachmeur D, Gallais H, Gastaut JA, Moreau J, Tamalet C: Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in southern France. J Clin Microb. 2004, 42: 570-577. 10.1128\/JCM.42.2.570-577.2004.","journal-title":"J Clin Microb"},{"key":"612_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1089\/088922203322230905","volume":"7","author":"E Brandin","year":"2003","unstructured":"Brandin E, Lindborg L, Gyllenstein K, Brostr\u00f6m C, Hagberg L, Gisslen M, Tuvesson B, Blaxhult A, Albert J: pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. AIDS Res Hum Retrovir. 2003, 7: 543-550. 10.1089\/088922203322230905.","journal-title":"AIDS Res Hum Retrovir"},{"key":"612_CR29","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/135965350400900422","volume":"9","author":"F Damond","year":"2004","unstructured":"Damond F, Matheron S, Peytavin G, Campa P, Taieb A, Collin G, Delaunay C, Ch\u00eane G, Brun-V\u00e9zinet F, Descamps D: Selection of K65R mutation in HIV-2 infected patients receiving tenofovir-containing regimen. Antivir Ther. 2004, 9: 635-636.","journal-title":"Antivir Ther"},{"key":"612_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/jmv.20174","volume":"74","author":"D Descamps","year":"2004","unstructured":"Descamps D, Damond F, Matheron S, Collin G, Campa P, Delarue S, Pueyo S, Ch\u00eane G, Brun-V\u00e9zinet F, French ANRS HIV-2 Cohort Study Group: High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol. 2004, 74: 197-201. 10.1002\/jmv.20174.","journal-title":"J Med Virol"},{"key":"612_CR31","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1128\/JCM.38.4.1370-1374.2000","volume":"38","author":"B Rod\u00e9s","year":"2000","unstructured":"Rod\u00e9s B, Holguin A, Soriano V, Dourana M, Mansinho K, Antunes F, Gonz\u00e1lez-Lahoz J: Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol. 2000, 38: 1370-1374.","journal-title":"J Clin Microbiol"},{"key":"612_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/00126334-200009010-00002","volume":"25","author":"ME van der Ende","year":"2000","unstructured":"van der Ende ME, Guillon C, Boers PH, Ly TD, Gruters RA, Osterhaus AD, Schutten M: Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr. 2000, 25: 11-18. 10.1097\/00042560-200009010-00002.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"612_CR33","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1089\/aid.2007.0034","volume":"23","author":"J Ruelle","year":"2007","unstructured":"Ruelle J, Sanou M, Liu HF, Vandenbroucke AT, Duquenne A, Goubau P: Genetic Polymorphisms and Resistance Mutations of HIV Type 2 in Antiretroviral-Naive Patients in Burkina Faso. AIDS Res Hum Retroviruses. 2007, 23: 955-964. 10.1089\/aid.2007.0034.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"612_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jviromet.2003.12.006","volume":"17","author":"J Ruelle","year":"2004","unstructured":"Ruelle J, Kabamba Mukadi B, Schutten M, Goubau P: Quantitative real-time PCR on Lightcycler\u00ae for the detection of human immunodeficiency virus type 2 (HIV-2). J Virol Meth. 2004, 17: 67-74. 10.1016\/j.jviromet.2003.12.006.","journal-title":"J Virol Meth"},{"key":"612_CR35","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1128\/jcm.32.7.1669-1673.1994","volume":"32","author":"I Van Kerckhoven","year":"1994","unstructured":"Van Kerckhoven I, Fransen K, Peeters M, De Beenhouwer H, Piot P, van der Groen GJ: Quantification of human immunodeficiency virus in plasma by RNA PCR, viral culture, and p24 antigen detection. J Clin Microbiol. 1994, 32: 1669-1673.","journal-title":"J Clin Microbiol"},{"key":"612_CR36","doi-asserted-by":"publisher","first-page":"F85","DOI":"10.1097\/00002030-199712000-00001","volume":"11","author":"PD Ghys","year":"1997","unstructured":"Ghys PD, Fransen K, Diallo MO, Etti\u00e8gne-Traor\u00e9 V, Coulibaly IM, Yebou\u00e9 KM, Kalish ML, Maurice C, Whitaker JP, Greenberg AE, Laga M: The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS. 1997, 11: F85-93. 10.1097\/00002030-199712000-00001.","journal-title":"AIDS"},{"key":"612_CR37","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1097\/00002030-200312050-00006","volume":"17","author":"S Matheron","year":"2003","unstructured":"Matheron S, Pueyo S, Damond F, Simon F, Lepr\u00eatre A, Campa P, Salamon R, Ch\u00eane G, Brun-Vezinet F, French HIV-2 Cohort Study Group: Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS. 2003, 17: 2593-2601. 10.1097\/00002030-200312050-00006.","journal-title":"AIDS"},{"key":"612_CR38","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1017\/S0950268806007709","volume":"135","author":"JH Humphrey","year":"2007","unstructured":"Humphrey JH, Nathoo KJ, Hargrove JW, Iliff PJ, Mutasa KE, Moulton LH, Chidawanyika H, Malaba LC, Zijenah LS, Zvandasara P, Ntozini R, Zunguza CD, Ward BJ, the ZVITAMBO Study Group: HIV-1 and HIV-2 prevalence and associated risk factors among postnatal women in Harare, Zimbabwe. Epidemiol Infect. 2007, 135: 933-942. 10.1017\/S0950268806007709.","journal-title":"Epidemiol Infect"},{"key":"612_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jviromet.2006.02.005","volume":"135","author":"RB Ferns","year":"2006","unstructured":"Ferns RB, Garson JA: Development and evaluation of a real-time RT-PCR assay for quantification of cell-free human immunodeficiency virus type 2 using a Brome Mosaic Virus internal control. J Virol Methods. 2006, 135: 102-108. 10.1016\/j.jviromet.2006.02.005.","journal-title":"J Virol Methods"},{"key":"612_CR40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/00002030-200302140-00006","volume":"17","author":"J Braun","year":"2003","unstructured":"Braun J, Plantier JC, Hellot MF, Tuaillon E, Gueudin M, Damond F, Malmsten A, Corrigan GE, Simon F: A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes. AIDS. 2003, 17: 331-336. 10.1097\/00002030-200302140-00006.","journal-title":"AIDS"},{"key":"612_CR41","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1128\/JCM.40.10.3654-3659.2002","volume":"40","author":"F Damond","year":"2002","unstructured":"Damond F, Gueudin M, Pueyo S, Farfara I, Robertson DL, Descamps D, Ch\u00e8ne G, Matheron S, Campa P, Brun-V\u00e9zinet F, Simon F: Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections. J Clin Microbiol. 2002, 40: 3654-3659. 10.1128\/JCM.40.10.3654-3659.2002.","journal-title":"J Clin Microbiol"},{"key":"612_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0166-0934(00)00177-4","volume":"88","author":"M Schutten","year":"2000","unstructured":"Schutten M, van den Hoogen B, van der Ende ME, Gruters RA, Osterhaus AD, Niesters HG: Development of a real-time quantitative RT-PCR for the detection of HIV-2 RNA in plasma. J Virol Methods. 2000, 88: 81-87. 10.1016\/S0166-0934(00)00177-4.","journal-title":"J Virol Methods"},{"key":"612_CR43","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1086\/339295","volume":"185","author":"GS Gottlieb","year":"2002","unstructured":"Gottlieb GS, Sow PS, Hawes SE, Ndoye I, Redman M, Coll-Seck AM, Faye-Niang MA, Diop A, Kuypers JM, Critchlow CW, Respess R, Mullins JI, Kiviat NB: Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis. 2002, 185: 905-914. 10.1086\/339295.","journal-title":"J Infect Dis"},{"key":"612_CR44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/prot.340100406","volume":"10","author":"A Gustchina","year":"1991","unstructured":"Gustchina A, Weber IT: Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases. Proteins. 1991, 10: 325-339. 10.1002\/prot.340100406.","journal-title":"Proteins"},{"key":"612_CR45","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1128\/JVI.74.3.1554-1557.2000","volume":"74","author":"SJ Popper","year":"2000","unstructured":"Popper SJ, Sarr AD, Gueye-Ndiaye A, Mboup S, Essex ME, Kanki PJ: Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo. J Virol. 2000, 74: 1554-1557. 10.1128\/JVI.74.3.1554-1557.2000.","journal-title":"J Virol"},{"key":"612_CR46","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1089\/aid.2006.22.1178","volume":"22","author":"R Parreira","year":"2006","unstructured":"Parreira R, Monteiro F, Padua E, Piedade J, Venenno T, Paix\u00e3o MT, Esteves A: Natural polymorphisms of HIV type 2 pol sequences from drug-naive individuals. AIDS Res Hum Retroviruses. 2006, 22: 1178-1182. 10.1089\/aid.2006.22.1178.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"612_CR47","volume-title":"10th European AIDS Conference\/EACS, 17\u201320","author":"J Ruelle","year":"2005","unstructured":"Ruelle J, Kabamba Mukadi B, Delferri\u00e8re N, Goubau P: Selection of resistance mutations in Human Immunodeficiency Virus type 2 (HIV-2) protease and reverse transcriptase [Abstract PE7.8\/1]. 10th European AIDS Conference\/EACS, 17\u201320. 2005, November , Dublin, Ireland"},{"key":"612_CR48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1128\/jvi.69.1.509-512.1995","volume":"69","author":"M Perach","year":"1995","unstructured":"Perach M, Rubinek T, Hizi A: Resistance to nucleoside analogs of selective mutants of human immunodeficiency virus type 2 reverse transcriptase. J Virol. 1995, 69: 509-512.","journal-title":"J Virol"},{"key":"612_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/01.aids.0000196171.35056.6c","volume":"20","author":"B Rod\u00e9s","year":"2006","unstructured":"Rod\u00e9s B, Toro C, Sheldon JA, Jim\u00e9nez V, Mansinho K, Soriano V: High rate of proV47A selection in patients failing lopinavir-based HAART. AIDS. 2006, 20: 127-129.","journal-title":"AIDS"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-8-21.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-8-21\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-8-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-8-21.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T17:55:33Z","timestamp":1684259733000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-8-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,27]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-8-21","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,27]]},"assertion":[{"value":"13 September 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"21"}}